20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
5 analysts have shared their evaluations of CryoPort (NASDAQ:CYRX) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for CryoPort, revealing an average target of $18.4, a high estimate of $21.00, and a low estimate of $17.00. Observing a 7.48% increase, the current average has risen from the previous average price target of $17.12.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive CryoPort is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Stanton | Jefferies | Raises | Buy | $21.00 | $17.00 |
| John Sourbeer | UBS | Raises | Neutral | $17.00 | $14.50 |
| Jacob Johnson | Stephens & Co. | Maintains | Equal-Weight | $17.00 | - |
| David Saxon | Needham | Lowers | Buy | $18.00 | $19.00 |
| David Saxon | Needham | Raises | Buy | $19.00 | $18.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CryoPort. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CryoPort compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CryoPort's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CryoPort's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on CryoPort analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into CryoPort's Background
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Key Indicators: CryoPort's Financial Health
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: CryoPort's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -5.13%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CryoPort's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -112.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CryoPort's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.19%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.9, caution is advised due to increased financial risk.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!